📊 CEROW Key Takeaways
Is Cero Therapeutics Holdings, Inc.. (CEROW) a Good Investment?
Cero Therapeutics is a pre-revenue biotech company in severe financial distress with negative stockholders' equity of -4.5M, indicating liabilities exceed assets. The company is burning cash at -1.5M annually with only 1.9M in cash reserves, providing less than 18 months of runway, while demonstrating a catastrophic ROA of -393.2% and inability to cover operating costs.
CERO Therapeutics appears to be a pre-revenue biotech with no demonstrated commercial traction, persistent operating losses, and deeply impaired balance sheet quality. While net loss improved year over year, the company still has negative equity, weak liquidity, and limited cash relative to its liabilities, which raises substantial going-concern and dilution risk. Fundamentally, the business needs clear clinical and financing progress before its financial profile can be viewed as stable.
Why Buy Cero Therapeutics Holdings, Inc.. Stock? CEROW Key Strengths
- Recent improvement in net loss (26.5% YoY reduction)
- Moderate insider activity suggesting management confidence
- Biopharmaceutical sector offers potential for high returns if pipeline succeeds
- Net loss improved year over year, indicating some expense moderation
- The company still holds cash on hand to support near-term operations
- Negative free cash flow is modest relative to reported operating loss, suggesting some non-cash charges
CEROW Stock Risks: Cero Therapeutics Holdings, Inc.. Investment Risks
- Negative stockholders' equity represents technical insolvency risk
- Insufficient cash runway (<18 months at current burn rate)
- Pre-revenue stage with no demonstrated commercial viability
- Extreme negative ROA indicates severe value destruction
- Liabilities exceed assets by 4.6M, creating balance sheet crisis
- Operating losses accelerating despite YoY improvement
- Critical liquidity crisis with current ratio of 0.30x
- No reported revenue, leaving the business entirely dependent on external funding
- Negative stockholders' equity and a 0.30x current ratio indicate severe balance-sheet stress
- Losses remain large relative to the asset base, with ROA of -393.2% signaling very weak capital efficiency
Key Metrics to Watch
- Cash balance and monthly burn rate trajectory
- Achievement of clinical development milestones
- Equity financing or capital raise announcements
- Operating expense management and cash runway extension
- Cash runway versus quarterly operating cash burn
- Liability reduction or equity restoration through financing and balance-sheet repair
Cero Therapeutics Holdings, Inc.. (CEROW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CEROW Profit Margin, ROE & Profitability Analysis
CEROW vs Healthcare Sector: How Cero Therapeutics Holdings, Inc.. Compares
How Cero Therapeutics Holdings, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cero Therapeutics Holdings, Inc.. Stock Overvalued? CEROW Valuation Analysis 2026
Based on fundamental analysis, Cero Therapeutics Holdings, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cero Therapeutics Holdings, Inc.. Balance Sheet: CEROW Debt, Cash & Liquidity
CEROW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cero Therapeutics Holdings, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1,248.64 indicates the company is currently unprofitable.
CEROW Revenue Growth, EPS Growth & YoY Performance
Cero Therapeutics Holdings, Inc.. Dividends, Buybacks & Capital Allocation
CEROW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cero Therapeutics Holdings, Inc.. (CIK: 0001870404)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CEROW
What is the AI rating for CEROW?
Cero Therapeutics Holdings, Inc.. (CEROW) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CEROW's key strengths?
Claude: Recent improvement in net loss (26.5% YoY reduction). Moderate insider activity suggesting management confidence. ChatGPT: Net loss improved year over year, indicating some expense moderation. The company still holds cash on hand to support near-term operations.
What are the risks of investing in CEROW?
Claude: Negative stockholders' equity represents technical insolvency risk. Insufficient cash runway (<18 months at current burn rate). ChatGPT: No reported revenue, leaving the business entirely dependent on external funding. Negative stockholders' equity and a 0.30x current ratio indicate severe balance-sheet stress.
What is CEROW's revenue and growth?
Cero Therapeutics Holdings, Inc.. reported revenue of N/A.
Does CEROW pay dividends?
Cero Therapeutics Holdings, Inc.. pays dividends, with $0.1M distributed to shareholders in the trailing twelve months.
Where can I find CEROW SEC filings?
Official SEC filings for Cero Therapeutics Holdings, Inc.. (CIK: 0001870404) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CEROW's EPS?
Cero Therapeutics Holdings, Inc.. has a diluted EPS of $-72.94.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CEROW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Cero Therapeutics Holdings, Inc.. has a STRONG SELL rating with 94% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CEROW stock overvalued or undervalued?
Valuation metrics for CEROW: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CEROW stock in 2026?
Our dual AI analysis gives Cero Therapeutics Holdings, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CEROW's free cash flow?
Cero Therapeutics Holdings, Inc..'s operating cash flow is $-1.5M, with capital expenditures of N/A.
How does CEROW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.30 (avg: 2).